Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033052 | 0.91 | SIGMAR1 (0.60) | SIGMAR1CHRM2CHRM1CHRM3SLC6A5 | |
| SCHEMBL6968971 | 0.84 | NPY5R (0.57) | SIGMAR1CHRM2CHRM1CHRM3SLC6A5 | |
| SCHEMBL16200816 | 0.83 | SIGMAR1 (0.52) | SIGMAR1CHRM2CHRM1CHRM3SLC6A5 | |
| SCHEMBL18569971 | 0.81 | KCNA3 (0.42) | CHRM2CHRM1CHRM3AKT1KCNA3 | |
| SCHEMBL16194574 | 0.81 | SLC6A5 (0.47) | SIGMAR1CHRM2CHRM1CHRM3SLC6A5 | |
| SCHEMBL16200819 | 0.79 | KCNH2 (0.48) | SIGMAR1NPY5RAKT1KCNA3CKS1B | |
| SCHEMBL648348 | 0.77 | SIGMAR1 (0.60) | SIGMAR1CHRM2CHRM1CHRM3AKT1 | |
| SCHEMBL915402 | 0.77 | KMT2A (0.65) | SIGMAR1DRD4KCNA3MCHR1 | |
| SCHEMBL23013177 | 0.76 | CACNA1I (0.61) | SIGMAR1NPY5RCXCR4CKS1BSKP1 | |
| SCHEMBL29508424 | 0.76 | CACNA1I (0.61) | SIGMAR1NPY5RCXCR4CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991981-B1 | DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9018215-B2 | Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018215-B2 | Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| WO-2014177469-A1 | DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323447-A1 | HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323447-A1 | HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323447-A1 | HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, SCNN1G | SIGMAR1 1090/4885CHRM2 1149/4885CHRM1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.